These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 22283769

  • 1. Inhibition of the renin-angiotensin-aldosterone system: how to obtain this.
    Pende A, Montecucco F.
    Curr Pharm Des; 2012; 18(7):950-1. PubMed ID: 22283769
    [No Abstract] [Full Text] [Related]

  • 2. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ.
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ.
    Contrib Nephrol; 2013 May; 179():7-14. PubMed ID: 23652444
    [Abstract] [Full Text] [Related]

  • 4. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F, Lang CC, Struthers AD.
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [Abstract] [Full Text] [Related]

  • 5. Renalism with Renin Angiotensin Aldosterone System Blockade: What Is the Consensus in Advanced Chronic Kidney Disease?
    Turino Miranda K, Ahmed SB.
    Can J Cardiol; 2024 Sep; 40(9):1729-1731. PubMed ID: 38777038
    [No Abstract] [Full Text] [Related]

  • 6. The blockade of renin-angiotensin-aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy.
    Morishita Y, Kusano E.
    Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):241-6. PubMed ID: 22023537
    [Abstract] [Full Text] [Related]

  • 7. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
    Mercier K, Smith H, Biederman J.
    Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
    [Abstract] [Full Text] [Related]

  • 8. RAAS inhibition and renal protection.
    Leoncini G, Viazzi F, Pontremoli R.
    Curr Pharm Des; 2012 Dec; 18(7):971-80. PubMed ID: 22283776
    [Abstract] [Full Text] [Related]

  • 9. [Renoprotective treatments : renin-angiotensin-aldosterone system blockade and beyond].
    Esnault V.
    Rev Prat; 2024 Jun; 74(6):s19-s22. PubMed ID: 39011717
    [Abstract] [Full Text] [Related]

  • 10. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH, Luft FC.
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [Abstract] [Full Text] [Related]

  • 11. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
    Hershon KS.
    Endocr Pract; 2011 Dec; 17(3):430-40. PubMed ID: 21454245
    [Abstract] [Full Text] [Related]

  • 12. Direct renin inhibitors: ONTARGET for success?
    Pasha Y, Gusbeth-Tatomir P, Covic A, Goldsmith D.
    Int Urol Nephrol; 2009 Dec; 41(2):341-55. PubMed ID: 19296235
    [Abstract] [Full Text] [Related]

  • 13. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ, Perkovic V, de Zeeuw D.
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [Abstract] [Full Text] [Related]

  • 14. Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.
    Oliveros E, Oni ET, Shahzad A, Kluger AY, Lo KB, Rangaswami J, McCullough PA.
    Cardiorenal Med; 2020 Dec; 10(2):69-84. PubMed ID: 32062648
    [Abstract] [Full Text] [Related]

  • 15. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH.
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [Abstract] [Full Text] [Related]

  • 16. Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?
    Lattanzio MR, Weir MR.
    Curr Hypertens Rep; 2010 Oct; 12(5):369-77. PubMed ID: 20703958
    [Abstract] [Full Text] [Related]

  • 17. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases!
    Waeber B.
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):216. PubMed ID: 22389390
    [No Abstract] [Full Text] [Related]

  • 18. The clinical potential of renin inhibitors and angiotensin antagonists.
    Cody RJ.
    Drugs; 1994 Apr; 47(4):586-98. PubMed ID: 7516858
    [Abstract] [Full Text] [Related]

  • 19. Navigating Renin-Angiotensin System Inhibitors in Patients with Declines in eGFR.
    Shulman R, Cohen JB.
    J Am Soc Nephrol; 2024 Oct 01; 35(10):1309-1311. PubMed ID: 39137049
    [No Abstract] [Full Text] [Related]

  • 20. [Pharmacological differences between inhibitor drugs of the renin-angiotensin aldosterone system].
    Méndez-Durán A.
    Rev Med Inst Mex Seguro Soc; 2011 Oct 01; 49(1):45-52. PubMed ID: 21513660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.